Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 19 Table 1 summarizes the eligibility criteria. Study design Quantitative (interventional or ...
The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...
Objective Biomarkers and FDA-Cleared Tools While existing tools represent decades of clinical and research development, they ...
Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...
We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...
Panome Bio, a CRO, launched MassID™, a cloud-based computational platform designed to improve how researchers process and interpret untargeted LC/MS metabolomics data. The platform is described in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results